PYY[3-36] administration decreases the respiratory quotient and reduces adiposity in diet-induced obese mice

Journal of Nutrition

Volumn 136, Issue 1, 2006, Pages 195-201

  Adams, Sean H ^a,b   Lei, Chunli ^a   Jodka, Carolyn M ^a   Nikoulina, Svetlana E ^a   Hoyt, Julie A ^a   Gedulin, Bronislava ^a   Mack, Christine M ^a   Kendall, Eric S ^a  

^a AMYLIN PHARMACEUTICALS INC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Gut peptide; Lipid; Metabolic syndrome; Obesity; oxidation

Indexed keywords

PEPTIDE YY; PEPTIDE YY[3-36]; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BODY WEIGHT; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFECT; ENERGY BALANCE; ENERGY EXPENDITURE; EPIDIDYMIS FAT; FATTY ACID OXIDATION; FECES; FOOD INTAKE; GALLBLADDER EMPTYING; LIPID METABOLISM; LIPID STORAGE; LIPOLYSIS; MALE; METABOLIC RATE; METABOLIC SYNDROME X; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OBESITY; RESPIRATORY QUOTIENT; WEIGHT REDUCTION;

ANIMALIA; RODENTIA;

EID: 31544480051     PISSN: 00223166     EISSN: 15416100     Source Type: Journal    
DOI: 10.1093/jn/136.1.195     Document Type: Conference Paper

References (33)

1. Adrian TE, Ferri GL, Bacarese-Hamilton AJ, Fuessl HS, Polak JM, Bloom SR. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology. 1985;89:1070-7.
2. Grandt D, Schimiczek M, Beglinger C, Layer P, Goebell H, Eysselein VE, Reeve JR Jr. Two molecular forms of peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1-36 and PYY 3-36. Regul Pept. 1994;51:151-9.
3. Alvarez Bartolome M, Borque M, Martinez-Sarmiento J, Aparicio E, Hernandez C, Cabrerizo L, Fernandez-Represa JA. Peptide YY secretion in morbidly obese patients before and after vertical banded gastroplasty. Obes Surg. 2002;12:324-7.
4. Batterham RL, Cohen MA, Ellis SM, Le Roux CW, Withers DJ, Frost GS, Ghatei MA, Bloom SR. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med. 2003;349:941-8.
5. Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL, Wren AM, Brynes AE, Low MJ, et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature. 2002;418:650-4.
6. Challis BG, Pinnock SB, Coll AP, Carter RN, Dickson SL, O'Rahilly S. Acute effects of PYY3-36 on food intake and hypothalamic neuropeptide expression in the mouse. Biochem Biophys Res Commun. 2003;311:915-9.
7. Adams SH, Won WB, Schonhoff SE, Leiter AB, Paterniti JR Jr. Effects of peptide YY[3-36] on short-term food intake in mice are not affected by prevailing plasma ghrelin levels. Endocrinology. 2004;145:4967-75.
8. Challis BG, Coll AP, Yeo GSH, Pinnock SB, Dickson SL, Thresher RR, Dixon J, Zahn D, Rochford JJ, et al. Mice lacking pro-opiomelanocortin are sensitive to high-fat feeding but respond normally to the acute anorectic effects of peptide-YY(3-36). Proc Natl Acad Sci U S A. 2004;101:4695-700.
9. Martin NM, Small CJ, Sajedi A, Patterson M, Ghatei MA, Bloom SR. Pre-obese and obese agouti mice are sensitive to the anorectic effects of peptide YY(3-36) but resistant to ghrelin. Int J Obes Relat Metab Disord. 2004;28:886-93.
10. Halatchev IG, Ellacott KL, Fan W, Cone RD. Peptide YY3-36 inhibits food intake in mice through a melanocortin-4 receptor-independent mechanism. Endocrinology. 2004;145:2585-90.
11. Pittner RA, Moore CX, Bhavsar SP, Gedulin BR, Smith PA, Jodka CM, Parkes DG, Paterniti JR, Srivastava VP, Young AA. Effects of PYY[3-36] in rodent models of diabetes and obesity.Int J Obes Relat Metab Disord. 2004;28:963-71.
12. Chelikani PK, Haver AC, Reidelberger RD. Intravenous infusion of peptide YY(3-36) potently inhibits food intake in rats. Endocrinology. 2005;146:879-88.
13. Koda S, Date Y, Murakami N, Shimbara T, Hanada T, Toshinai K, Niiji A, Furuya M, Inomata N, et al. The role of the vagal nerve in peripheral PYY3-36-induced feeding reduction in rats. Endocrinology. 2005;146:2369-75.
14. Pappas TN, Debas HT, Chang AM, Taylor IL. Peptide YY release by fatty acids is sufficient to inhibit gastric emptying in dogs. Gastroenterology. 1986;91:1386-9.
15. Hoentjen F, Hopman WP, Jansen JB. Effect of circulating peptide YY on gallbladder emptying in humans. Scand J Gastroenterol. 2001;36:1086-91.
16. Lluis F, Fujimura M, Lonovics J, Guo YS, Gomez G, Greeley GH Jr, Townsend CM Jr, Thompson JC. Peptide YY and gallbladder contraction. Studies in vivo and in vitro. Gastroenterology. 1988;94:1441-6.
17. Tatemoto K, Mutt V. Isolation of two novel candidate hormones using a chemical method for finding naturally occurring polypeptides. Nature. 1980;285:417-8.
18. Yang H. Central and peripheral regulation of gastric acid secretion by peptide YY. Peptides. 2002;23:349-58.
19. Moran TH, Smedh U, Kinzig KP, Scott KA, Knipp S, Ladenheim EE. Peptide YY(3-36) inhibits gastric emptying and produces acute reductions in food intake in rhesus monkeys. Am J Physiol Regul Integr Comp Physiol. 2005;288:R384-8.
20. Surwit RS, Feinglos MN, Rodin J, Sutherland A, Petro AE, Opara EC, Kuhn CM, Rebuffe-Scrive M. Differential effects of fat and sucrose on the development of obesity and diabetes in C57BL/6J and A/J mice. Metabolism. 1995;44:645-51.
21. Lusk G. The elements of the science of nutrition. 4th ed. Philadelphia: W.B. Saunders; 1928.
22. Heffernan MA, Jiang WJ, Thorburn AW, Ng FM. Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism. Am J Physiol Endocrinol Metab. 2000;279:E501-7.
23. Saha AK, Ruderman NB. Malonyl-CoA and AMP-activated protein kinase: an expanding partnership. Mol Cell Biochem. 2003;253:65-70.
24. Lafontan M. Fat Cells: Afferent and Efferent Messages Define New Approaches to Treat Obesity. Annu Rev Pharmacol Toxicol. 2005;45:119-46.
25. Himms-Hagen J. Food restriction increases torpor and improves brown adipose tissue thermogenesis in ob/ob mice. Am J Physiol. 1985;248:E531-9.
26. Williams TD, Chambers JB, Henderson RP, Rashotte ME, Overton JM. Cardiovascular responses to caloric restriction and thermoneutrality in C57BL/6J mice. Am J Physiol Regul Integr Comp Physiol. 2002;282:R1459-67.
27. Castan I, Valet P, Voisin T, Quideau N, Laburthe M, Lafontan M. Identification and functional studies of a specific peptide YY-preferring receptor in dog adipocytes. Endocrinology. 1992;131:1970-6.
28. Labelle M, Boulanger Y, Fournier A, St Pierre S, Savard R. Tissue-specific regulation of fat cell lipolysis by NPY in 6-OHDA-treated rats. Peptides. 1997;18:801-8.
29. Serradeil-Le Gal C, Lafontan M, Raufaste D, Marchand J, Pouzet B, Casellas P, Pascal M, Maffrand JP, Le Fur G. Characterization of NPY receptors controlling lipolysis and leptin secretion in human adipocytes. FEBS Lett. 2000;475:150-6.
30. van den Hoek AM, Heijboer AC, Corssmit EP, Voshol PJ, Romijn JA, Havekes LM, Pijl H. PYY3-36 reinforces insulin action on glucose disposal in mice fed a high-fat diet. Diabetes. 2004;53:1949-52.
31. Ikemoto S, Takahashi M, Tsunoda N, Maruyama K, Itakura H, Kawanaka K, Tabata I, Higuchi M, Tange T, et al. Cholate inhibits high-fat diet-induced hyperglycemia and obesity with acyl-CoA synthetase mRNA decrease. Am J Physiol. 1997;273:E37-45.
32. Jandacek RJ, Heubi JE, Tso P. A novel, noninvasive method for the measurement of intestinal fat absorption. Gastroenterology. 2004;127:139-44.
33. Henry M, Ghibaudi L, Gao J, Hwa JJ. Energy metabolic profile of mice after chronic activation of central NPY Y1, Y2, or Y5 receptors. Obes Res. 2005;13:36-47.